:: Library Catalog

Cover Image

Saved in:

Bibliographic Details
Main Authors:	Saqr Alsakarneh, Omar Al Ta’ani, Razan Aburumman, Inas Mikhail, Jana G. Hashash, Francis A. Farraye
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	https://onlinelibrary.wiley.com/doi/10.1111/apt.70139
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Primary Sclerosing Cholangitis in the Absence of Inflammatory Bowel Disease Increases the Risk of Colorectal Cancer: A Multi‐Centre Propensity Score Matched Analysis
by: Saqr Alsakarneh, et al.
Published: (2025)

Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease
by: Aakash Desai, et al.
Published: (2024)

IL23 Receptor Polymorphism Is a Predictor of Anti‐Tumour Necrosis Factor‐α‐Induced Paradoxical Psoriasis in Inflammatory Bowel Disease
by: Navneet Natt, et al.
Published: (2025)

Editorial: JAK to JAK—Navigating Intra‐Class JAK Inhibitor Switching in Inflammatory Bowel Disease. Authors' Reply
by: Mathieu Uzzan, et al.
Published: (2025)

Autoimmune Hepatitis and Vitamin D Deficiency: A Nationwide Perspective
by: Yassine Kilani, et al.
Published: (2024)

Meta‐Analysis: Improvement of Bowel Urgency With Advanced Therapies for Inflammatory Bowel Disease
by: Purab Patel, et al.
Published: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease
by: Jeli Mendoza, et al.
Published: (2024)

Obesity Is Associated With Worsened Outcomes in Patients With Ulcerative Colitis on Advanced Therapies: A Propensity Matched Cohort Study From the U.S.
by: Aakash Desai, et al.
Published: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease?
by: Matthew D. Coates, et al.
Published: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease
by: Marco Vincenzo Lenti, et al.
Published: (2025)

Systematic Review: Stigma Associated With Inflammatory Bowel Disease
by: Suprabhat Giri, et al.
Published: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease?
by: Agnes Hiu Yan Ho, et al.
Published: (2025)

Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study
by: Ronen Stein, et al.
Published: (2025)

Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
by: Uma Mahadevan, et al.
Published: (2025)

Meta‐Analysis: Prevalence of Eating Disorders in Inflammatory Bowel Disease
by: Quinn Goddard, et al.
Published: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
by: Jianhui Zhao, et al.
Published: (2024)

Letter: The Persistence of Anxiety and Depression in Inflammatory Bowel Disease: A Core Phenotype Beyond Inflammatory Activity
by: Brigida Barberio, et al.
Published: (2026)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
by: Fai Fai Ho, et al.
Published: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues
by: Stephanie Gold, et al.
Published: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
by: Suprabhat Giri, et al.
Published: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
by: Bharati Kochar, et al.
Published: (2025)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease
by: Nicholas Clark, et al.
Published: (2025)

Meta‐Analysis: Pregnancies With Inflammatory Bowel Disease Complicated by Intrahepatic Cholestasis of Pregnancy
by: Shamim Joudaki, et al.
Published: (2025)

Overall and Comparative Risk of Shingles With Advanced Therapies in Patients With Inflammatory Bowel Diseases
by: Dhruv Ahuja, et al.
Published: (2025)

Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide
by: Lynna Chen, et al.
Published: (2025)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet?
by: Joyce Wing Yan Mak
Published: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply
by: Jessica A. Fitzpatrick, et al.
Published: (2025)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply
by: Cristina Rubín de Célix, et al.
Published: (2025)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease
by: Cong Dai, et al.
Published: (2024)

Editorial: Shooting in the Dark—The Problem With Empiric Antispasmodics for Abdominal Pain in Inflammatory Bowel Disease
by: Jane Lim, et al.
Published: (2025)

Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story?
by: Liang Jiao, et al.
Published: (2026)

Prevalence and Predictors of Symptoms of Anxiety or Depression at Diagnosis in Patients With Inflammatory Bowel Disease: An Inception Cohort
by: Christy Riggott, et al.
Published: (2025)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients With Inflammatory Bowel Disease
by: Chang Liu, et al.
Published: (2026)

Persistence of Symptoms of Anxiety and Depression in Inflammatory Bowel Disease: A Longitudinal Follow‐Up Study
by: Christy Riggott, et al.
Published: (2025)

Maternal and Perinatal Outcomes in Pregnant Women With Comorbid Inflammatory Bowel Disease and Chronic Liver Disease
by: Jessica D. Lee, et al.
Published: (2025)

Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease?
by: Konstantinos Papamichael, et al.
Published: (2024)

Systematic Review: Ultrasound Goes Echo—Decarbonising Inflammatory Bowel Disease Care Through Intestinal Ultrasound
by: Sara Massironi, et al.
Published: (2025)

Mild Endoscopic Disease Activity Is Associated With Adverse Outcomes Among Older Adults With Inflammatory Bowel Disease
by: Catherine Z. Tang, et al.
Published: (2025)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply
by: Isabel Carbery, et al.
Published: (2024)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet? Author's Reply
by: Aurelien Amiot, et al.
Published: (2025)